Tazemetostat is a potent (Ki = 2.5nM wild type human PRC2-containing) and selective SAM-competitive inhibitor of the lysine methyltransferase EZH2.1 Tazemetostat displayed strong antiproliferative effects against SMARCB1-deleted malignant rhabdoid tumor
* VAT and and shipping costs not included. Errors and price changes excepted